INO-4800 COVID-19 Vaccine Description
INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, which causes the COVID-19 disease in humans.
INOVIO s INO-4800 is the only nucleic-acid-based vaccine stable at room temperature for more than a year and does not require frozen transport or for years of storage, which are important factors when implementing mass immunizations to battle the current pandemic, says INOVIO.
The INO-4800 vaccine contains the plasmid pGX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2.
Inovio s proprietary platform hand-held smart device called CELLECTRA® leads the way forward for activation immunotherapy. CELLECTRA uses a brief electrical pulse to open small pores in the cell reversibly to allow the plasmids to enter.
Share this article
Share this article
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. A 25% or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment. Three out of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. By comparison, the spontaneous resolution of vulvar HSIL caused by HPV-16/18 is estimated to be only 2%. The trial also showed VGX-3100 to be safe and well-tolerated. Based upon these results INOVIO is planning
Press release content from Business Wire. The AP news staff was not involved in its creation.
Alachua’s Life Sciences Ecosystem Raises Over $1.0 Billion in 2020
January 6, 2021 GMT
ALACHUA, Fla. (BUSINESS WIRE) Jan 6, 2021
UF Innovate | Sid Martin Biotech announces the City of Alachua’s life sciences industry has raised more than $1 billion in 2020. The life sciences community has accelerated growth with government grants and contracts, mergers and acquisitions, successful financing rounds, and sales revenue.
In 2020 alone UF Innovate | Sid Martin Biotech’s resident companies, members and alumni raised over $462,660,054 in outside investment, $282,400,002 in government contracts, and $4,470,107 in grants. In addition, as of the third quarter for calendar year 2020 annual sales for incubator residents, members and alumni is approximately $236,114,506. In 2019 these companies raised over $2.3 billion, which includes Thermo Fisher’s acquisition of Sid Martin alum and Alach
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases
Search jobs 24-Dec-2020 INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet s EClinicalMedicine
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in
EClinicalMedicine, an open access clinical journal published by The Lancet.
The paper, titled Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial, found that INO-4800 was immunogenic in all vaccinated subjects, effectively generating an immune response of humoral (including neutralizing antibodies) and/or cellular re